The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets.
about
Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).High-grade undifferentiated pleomorphic sarcoma of the pelvis: A case report and review of literature.Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma
P2860
The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
The angiogenic asset of soft t ...... cover new therapeutic targets.
@en
type
label
The angiogenic asset of soft t ...... cover new therapeutic targets.
@en
prefLabel
The angiogenic asset of soft t ...... cover new therapeutic targets.
@en
P2093
P2860
P356
P1433
P1476
The angiogenic asset of soft t ...... scover new therapeutic targets
@en
P2093
Laura Rocchi
Roberto Perris
Stefano Caraffi
P2860
P304
P356
10.1042/BSR20140075
P5008
P577
2014-11-04T00:00:00Z